Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.
作者： Kozo Nagai , Lihong Hou , Li Li , Bao Nguyen , Tessa Seale
DOI: 10.18632/ONCOTARGET.25972
关键词: Tyrosine-kinase inhibitor 、 Acute promyelocytic leukemia 、 Leukemia 、 Arsenic trioxide 、 Medicine 、 Myeloid leukemia 、 Protein kinase B 、 Sorafenib 、 Cancer research 、 Tyrosine kinase
摘要: … This result shows that ATO preferably induces poly-ubiqutination of mutant FLT3/ITD protein … also reduces expression of HOXA9 and MEIS1. HOXA9 regulates its own expression by a …
elsevier.com
sci-hub.st 参考文章(57)
Y Minami, H Kiyoi, Y Yamamoto, K Yamamoto, R Ueda, H Saito, T Naoe, Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. ,vol. 16, pp. 1535- 1540 ,(2002) , 10.1038/SJ.LEU.2402558
M. Cavigelli, W. W. Li, A. Lin, B. Su, K. Yoshioka, M. Karin, The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. The EMBO Journal. ,vol. 15, pp. 6269- 6279 ,(1996) , 10.1002/J.1460-2075.1996.TB01017.X
Byoung K. Kim, Jung M. Hyun, Chul W. Jung, Woo H. Park, Jae G. Seol, Chung C. Lee, Young Y. Lee, Eun S. Kim, Arsenic Trioxide-mediated Growth Inhibition in MC/CAR Myeloma Cells via Cell Cycle Arrest in Association with Induction of Cyclin-dependent Kinase Inhibitor, p21, and Apoptosis Cancer Research. ,vol. 60, pp. 3065- 3071 ,(2000)
Wensheng Yan, Yong-Sam Jung, Yanhong Zhang, Xinbin Chen, Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase PLoS ONE. ,vol. 9, pp. e103497- ,(2014) , 10.1371/JOURNAL.PONE.0103497
Andrew M Evens, Martin S Tallman, Ronald B Gartenhaus, The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leukemia Research. ,vol. 28, pp. 891- 900 ,(2004) , 10.1016/J.LEUKRES.2004.01.011
M Levis, D Small, FLT3: ITDoes matter in leukemia. Leukemia. ,vol. 17, pp. 1738- 1752 ,(2003) , 10.1038/SJ.LEU.2403099
Maria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, Francesca Milano, Sara Pierangeli, Floriana Mulas, Roberta Pacini, Alessia Tabarrini, Valentina Pettirossi, Roberta Rossi, Calogero Vetro, Lorenzo Brunetti, Paolo Sportoletti, Enrico Tiacci, Francesco Di Raimondo, Brunangelo Falini, Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells Blood. ,vol. 125, pp. 3455- 3465 ,(2015) , 10.1182/BLOOD-2014-11-611459
Steven Knapper, Alan K. Burnett, Tim Littlewood, W. Jonathan Kell, Sam Agrawal, Raj Chopra, Richard Clark, Mark J. Levis, Donald Small, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. ,vol. 108, pp. 3262- 3270 ,(2004) , 10.1182/BLOOD-2006-04-015560
Olivier Legrand, Rita Hleihel, Umut Sahin, Nadim Tawil, Ala Salameh, Kazem Zibara, Nadine Darwiche, Mohamad Mohty, Hervé Dombret, Pierre Fenaux, Hugues de Thé, Ali Bazarbachi, Hiba El Hajj, Zeina Dassouki, Caroline Berthier, Emmanuel Raffoux, Lionel Ades, Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. ,vol. 125, pp. 3447- 3454 ,(2015) , 10.1182/BLOOD-2014-11-612416
Qun Liu, Susan Hilsenbeck, Yair Gazitt, Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. ,vol. 101, pp. 4078- 4087 ,(2003) , 10.1182/BLOOD-2002-10-3231